The Psychedelics Newsletter

Psychedelic healthcare and PTSD, Study finds few differences between effects of psilocybin and LSD, The regulatory landscape of psychedelic healthcare in Europe is evolving.

Patenting psychedelic medicines, Research conducted on psilocybin therapy's durability, Can psilocybin become a legitimate mental health treatment?

PSYCH Symposium: London 2022 - Europe's premier psychedelic medicine conference, Oregon releases draft rules for psilocybin framework, Mindstate Design Labs raises US$11.5m

Cybin on converting psychedelic molecules; Psychedelic medicines offer treatment for eating disorders; Oregon proposes ban on synthetic psilocybin

Psychedelic profiles: LSD, Should psychedelics be more widely available? Virginia decriminalisation bill defeated in Senate committee hearing.

Psychedelic profiles: ibogaine; Eleusis goes public via merger, creating a US$450 million company; The future of psychedelic medicine will be drugs you’ve never heard of.

Psychedelic profiles: ketamine; Italian officials certify signatures for psilocybin referendum; Sixty-five per cent of Americans with mental health conditions want access to psychedelics.

Psychedelic profiles: psilocybin; Awakn releases data from Phase II study for alcohol use disorder; Canada amends Special Access Program for psychedelic medicines.

Psychedelic profiles: MDMA; The promises and perils of psychedelic healthcare; Psychedelic drug firm gets rare endorsement from big pharma.

Psychedelic healthcare in 2021; Ketamine for the treatment of mental health disorders; Ketamine therapy is going mainstream, are we ready?

Gwella on making microdosing mainstream; The MHRA releases new guidance on using data in clinical trials; Psychedelics: the newest tool in nuclear negotiations?

Healthcare professionals’ perception of psychedelic medicines; Australian regulator refuses to reclassify psychedelic compounds; COMPASS shares further data from COMP360 Phase IIb trial